Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fortune magazine mention’s of CCTL will bring large whales on Tuesday and will gauge it past a dime. IMO
Thanks to traders, I have been holding ADTM since this news release.
Sorry to see you go this one is a diamond in the rufffff $PacB
I heard yesterday on Bloomberg, BTC going to 100k this year, a lots room here to move.
Not aware of it, the OTC says 3.9 B outstanding, by the way that stock jumped 0.45 just in one day.... the possibilities ARE just enormous here. $PVDG a dream maker for all.
Just to show you how one company went from $0.0001 to $1.60 in 6 months CARRING 4 billion shares on its back. $PVDG's GREAT management will do just fine in less time and less OS. Good luck to everyone.
https://ih.advfn.com/stock-market/USOTC/tesoro-enterprises-pk-TSNP/stock-price
Was it a coincidence that the FDA interfered with INO's Progress, was it Big Pharma,(Moderna RNA versus INO's DNA) was it politics or was it corruption and bribing that cleared the way for some and caused some to tumble? inquiring minds like to know.............
Its all here about INO accomplishments.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30266-X/fulltext
RAPID CREATION OF A NOVEL, INVESTIGATIONAL
COVID-19 DNA VACCINE
INOVIO has demonstrated that DNA medicines can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response in clinical trials involving more than 2,000 patients in 7,000 administrations. The advantages of INOVIO’s DNA medicines platform in a pandemic situation like the world is now facing with COVID-19 are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require frozen storage and transport; and their robust immune response as well as favorable safety and tolerability profile.
INOVIO IS A LEADER IN CORONAVIRUS DNA
VACCINE DEVELOPMENT
INOVIO scientists are coronavirus experts. INOVIO was the first to advance its DNA vaccine INO-4700 against MERS CoV, a related coronavirus, into evaluation in humans. INOVIO is currently preparing to initiate a Phase 2 vaccine trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred.
In a recently published paper in Lancet Infectious Diseases, INOVIO’s Phase 1 study of its MERS-CoV vaccine demonstrated it was well tolerated and furthermore induced high levels of antibody responses in roughly 95% of study participants. Durable antibody and T cell immune responses to INO-4700 were also maintained through 60 weeks following dosing.
COLLABORATING TO MEET AN URGENT HEALTH NEED
INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance INO-4800:
R&D collaborators to date include the Wistar Institute, the University of Pennsylvania, the University of Texas, Fudan University and the Laval University.
INOVIO has partnered with Advaccine and the International Vaccine Institute to advance clinical trials of INO-4800 in China and South Korea, respectively.
INOVIO is also assessing preclinical efficacy of INO-4800 in several animal challenge models with Public Health England (PHE) and Commonwealth Scientific and Industrial Research Organisation (CSIRO) in Australia.
INOVIO is also working with a team of contract manufacturers including VGXI, Inc., Richter-Helm BioLogics, and Ology Biosciences to produce INO-4800 and seeking additional external funding and partnerships to scale up manufacturing capacities to satisfy the urgent global demand for a safe and effective vaccine.
To date, the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation, and the U.S. Department of Defense have contributed significant funding to the advancement and manufacturing of INO-4800.
https://www.inovio.com/our-focus-serving-patients/covid-19/
it is becoming a habitual tactic where NIO P/S slide down on good news. Ain't worried, been there and shall be here for years to come... you thought Tesla is big? NIO will be bigger in due time! $$$$INO
Congress plans hearings after GameStop stock frenzy
https://www.cbsnews.com/news/gamestop-robinhood-trading-freeze-congress-hearings/
Must be BLACKROCK and Federated Hermes, and many more!
CATB, 20 million S/OS as of 10/30/20. Wide vertical space to leap just like a cat! $CATB
Thanks Fress, I will check it it and follow.GL
Why Inovio Pharmaceuticals Could Be Headed For A GameStop-Like Short Squeez
https://seekingalpha.com/article/4401617-why-inovio-pharmaceuticals-be-headed-for-gamestop-like-short-squeeze?utm_campaign=twitter_automated&utm_content=article&utm_medium=social&utm_source=twitter_automated
$INO Mentioned here on GME Twitter=>
the safest covid vaccine $INO with 56m shares shorted, bigpharma dont want better vaccines come out so WS is shorting them, let´s show how we want this pandemia stop with better vaccines, SQUEEZEEEEE the shorts!
https://twitter.com/search?q=%24GME&src=typeahead_click
because it was shorted, it is time to pay i guess. be patient, this turtle will win the race! IMO $$$$INO
Lakers...Sorry, no body cares or listening to Kim! you have to walk the walk and talk the talk like MRNA, NVAX, BNTX PFE and others, KIM ain't the man who can do it...that is why nobody is mentioning INO anymore. JNJ is almost there with their DNA vaccine, room temperature and all....
Bill Gates have been accused of many Hoaxes, he is too smart to tarnish his image...
Now is the time for this turtle (INO)to start crawling, while others are freezing their inventory!
$INO
[/Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of the Company's first commercial product, ANJESO, began in June of 2020. Baudax's New Drug Application for ANJESO was approved by FDA on February 20, 2020 for the management the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. As a non-opioid, IV meloxicam has the potential to overcome many of the issues associated with commonly prescribed opioid therapeutics, including respiratory depression, constipation, excessive nausea and vomiting, as well as having no addictive potential while maintaining meaningful analgesic effects for relief of pain. For more information please visit www.baudaxbio.com.
$BXRX
crossed resistance limits, no body knows how hi it will go!
100% BUY! $TRXC
https://www.barchart.com/stocks/quotes/TRXC/opinion
That $150B From MR BIDEN for Vaccines...I wonder how much of it will go to INO? if any that is!
tell me about it, you are not the only one!
Though Old news but it tells what Patrick Netter is All about=>
will you say $60 by Friday?
What is keeping this ticker down? between todays news and the DOD money its over half of $ Billion...mind boggling!
PacBio’s Never Been Stronger: New CEO, Christian Henry, Shares His Vision
Christian Henry, CEO, PacBio
2020 show mp3
https://mendelspod.com/podcasts/pacbio%E2%80%99s-never-been-stronger-new-ceo-christian-henry-shares-his-vision/
Captain Kim is unable to guide the INO’s ship to free sailing, we are stuck @ ground level. Pity
WHO says authorities investigating new COVID-19 variant in England
https://mobile.reuters.com/article/amp/idUSKBN28O2DI?__twitter_impression=true
10% to 15% of volunteers reporting side effects that were “significantly noticeable.” coronavirus vaccine czar said Tuesday that Pfizer’s and Moderna’s
Thank you Gew59! I missed to read that news $INO
Exactly Lakers, November is what he said...
[quotInovio declined to say exactly when it submitted its response.
"We look forward to hearing back from the FDA in November and continue to prepare for a planned phase-II/III trial of INO-4800," Inovio said in a statement provided to the Philadelphia Business Journal. "As a reminder, the partial clinical hold by the FDA is not due to the occurrence of any adverse events related to Inovio’s ongoing expanded phase-I study of INO-4800, which has continued, and does not impact the advancement of Inovio's other product candidates in development.e][/quote]
What happened to the FDA lifting the partial hold, it is November 30th???
Ino was just mentioned by Bloomberg,(@ 5:10 PM East) as a traditional vaccine compared to others.
PACBIO virtual 2020 Global summit!
https://twitter.com/PacBio/status/1329464490971303938/photo/1
$PacB
JUST SAYING....Digest the news and think......Why ARE We still trading @$10?
INOVIO Announces Initiation of Phase 2 Segment of its Phase 2/3 Clinical Trial for its COVID-19 DNA Vaccine Candidate, INO-4800; Trial Will Be Funded by the U.S. Department of Defense
November 16, 2020
DownloadPDF Format (opens in new window)
PLYMOUTH MEETING, Pa., Nov. 16, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800, its COVID-19 vaccine candidate. The planned Phase 2/3 clinical trial, called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy), is a randomized, blinded, placebo-controlled safety and efficacy trial of INO-4800 to be conducted in adults in the U.S. The INNOVATE trial will be funded by the U.S. Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA).
The Phase 2 segment of the trial is designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization to receive either INO-4800 or placebo for each dose to confirm the more appropriate dose(s) for each of three age groups with high risks of infection (18-50 years, 51-64 years and 65 years and older) for the subsequent Phase 3 efficacy evaluation. The Phase 3 segment of the INNOVATE trial remains on partial clinical hold until INOVIO satisfactorily resolves the FDA's remaining questions related to the CELLECTRA® 2000 device that will be used to deliver INO-4800 directly into the skin. The company plans to resolve the remaining device questions during the conduct of Phase 2 segment and prior to the start of the Phase 3 segment of the trial.
"I am extremely proud of the INOVIO team, which has been working tirelessly to develop a safe and effective vaccine in the fight against the COVID-19 pandemic. Initiation of our Phase 2 trial marks a pivotal milestone for INO-4800," said INOVIO's President and CEO, Dr. J. Joseph Kim. "We are especially pleased to continue our partnership with the DoD to advance the development of INO-4800 for active duty service members and civilian personnel and are grateful for the Department's continued confidence in our technology to combat COVID-19."
Dr. Kim continued, "INO-4800's key differentiators are the safety and tolerability data we have observed thus far, as well as its excellent thermostability profile – making it possible to manufacture at scale and transport without frozen cold chain requirements. INO-4800 also maintains the ability to be safely re-administered and is differentiated by its ability to stimulate both CD4+ and CD8+ T cell responses."
The FDA's authorization to proceed is based on its review of INOVIO's non-clinical data, device information and interim Phase 1 safety and immunogenicity data as well as its design and plans for the Phase 2 and Phase 3 segments of the planned clinical trial. The Phase 2 segment of the trial is expected to enroll approximately 400 participants at up to 17 U.S. sites to evaluate safety and immunogenicity in order to confirm the dose(s) for the subsequent efficacy evaluation planned for the Phase 3 segment.
The DoD has agreed to provide funding for both the Phase 2 and Phase 3 segments of the INNOVATE clinical trial, in addition to the $71 million of funding previously announced in June for the large-scale manufacture of the company's proprietary smart device CELLECTRA® 3PSP and the procurement of CELLECTRA® 2000 devices.
About the INO-4800 "INNOVATE" Phase 2/3 Clinical Trial
The lead Principal Investigator for the INNOVATE trial is Dr. Pablo Tebas, Professor of Medicine at the Hospital of the University of Pennsylvania. The Phase 2 segment of the trial is designed to evaluate safety, tolerability and immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a three-to-one randomization to receive either INO-4800 or placebo for each dose, to confirm the more appropriate dose(s) for each of three age groups (18-50 years, 51-64 years and 65 years and older) for the subsequent Phase 3 efficacy evaluation. The company intends to work diligently to ensure diversity in enrollment, targeting specific populations that are working or residing in environments with high infection rates and/or areas where there is greater risk of exposure to SARS-CoV-2, for whom exposure may be relatively prolonged or for whom personal protective equipment (PPE) may be inconsistently used, especially in confined settings.
In the Phase 3 segment of the trial, INOVIO intends to enroll healthy men and non-pregnant women 18 years and older, to evaluate the efficacy of the proposed dose(s) based on the data from the Phase 2 evaluation. Participants will be enrolled in a one-to-one randomization to receive either INO-4800 or a placebo. The Phase 3 segment will be case-driven with the final number of enrollees to be determined by the incidence of COVID-19 during the Phase 3 segment. The primary endpoint of the Phase 3 segment will be virologically confirmed COVID-19 disease.
About INOVIO's Global Coalition Advancing INO-4800
INOVIO has assembled a global coalition of collaborators, partners and funders to rapidly advance the development of INO-4800. R&D collaborators to date include the Wistar Institute, the University of Pennsylvania, the University of Texas, Fudan University and Laval University. INOVIO has partnered with Advaccine and the International Vaccine Institute to conduct clinical trials of INO-4800 in China and South Korea, respectively. INOVIO is also assessing nonclinical efficacy of INO-4800 in several animal challenge models with Public Health England (PHE) and Commonwealth Scientific and Industrial Research Organization (CSIRO) in Australia. INOVIO is working with a team of contract manufacturers including Thermo Fisher Scientific, Richter-Helm BioLogics, and Ology Bioservices to manufacture INO-4800 on a commercial scale and is seeking additional external funding and partnerships to further scale up manufacturing capacities to satisfy the urgent global demand for safe and effective vaccines. To date, the Coalition for Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation, and the U.S. Department of Defense have contributed significant funding to the advancement and manufacturing of INO-4800.
About INO-4800
INO-4800 is INOVIO's DNA vaccine candidate intended to protect against SARS-CoV-2, the novel coronavirus that causes COVID-19. INOVIO has extensive experience working with coronaviruses and was the first company to initiate a Phase 2a trial for INO-4700, a vaccine for Middle East Respiratory Syndrome (MERS), another coronavirus related to SARS-CoV-2.
INO-4800 is the only nucleic-acid based vaccine that is stable at room temperature for more than a year and does not need to be frozen in transport of storage, which are important factors when implementing mass immunizations.
About INOVIO's DNA Medicines Platform
INOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with MERS and COVID-19 diseases being developed under grants from the Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S. Department of Defense. DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.
INOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA®. The CELLECTRA device uses a brief electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a key limitation of other DNA and other nucleic acid approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the cell to produce the targeted antigen. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. Administration with the CELLECTRA device ensures that the DNA medicine is efficiently delivered directly into the body's cells, where it can go to work to drive an immune response. INOVIO's DNA medicines do not interfere with or change in any way an individual's own DNA. The advantages of INOVIO's DNA medicine platform are how fast DNA medicines can be designed and manufactured; the stability of the products, which do not require freezing in storage and transport; and the robust immune response, safety profile, and tolerability that have been observed in clinical trials.
With more than 2,000 patients receiving INOVIO investigational DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO has a strong track record of rapidly generating DNA medicine candidates with potential to meet urgent global health needs.
http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Initiation-of-Phase-2-Segment-of-its-Phase-23-Clinical-Trial-for-its-COVID-19-DNA-Vaccine-Candidate-INO-4800-Trial-Will-Be-Funded-by-the-U.S.-Department-of-Defense/default.aspx
Great job Lakers, there is no doubt that we are trading @ this level because of some higher powers, DOD will eventually surprise everyone and (time will tell) that INO has the best Vaccine....$INO
The general said CVS will do the job! Lucky in @ $55
that is too deep of a dip, you will be lucky to get a dip at $35. IMO
Just think, soon, means any day in November, FDA approves or lifts its partial hold to start P2/3, funding will come from all directions on top of its $337 millions cash on hand. Not to mention when NEJM P1PR gets published then $30 will not just be an easy reach, but will be a thing of the past. and that is IMO.